Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study

Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background and Aims: Pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) treatment of chronic hepatitis C virus (HCV) infection is associated with a substantially elevated risk of discontinuation. The aim of this study is to evaluate the reason for premature discontinuation during PEG-IFN α-2b and RBV treatment due to adverse effects in patients with chronic HCV infection. Methods: A total of 2871 Japanese patients who had chronic HCV infection treated with PEG-IFN α-2b and RBV were screened. We prospectively investigated the reasons for premature discontinuation of treatment classified by sex and age, and analyzed the timing of discontinuation. Results: Of the 2871 patients, 250 (8.7%) discontinued treatment because of adverse effects. The main reasons for premature discontinuation were neurovegetative symptoms (n=77, 30.8%), depression-related syndrome (n=46, 18.4%), hematologic effects (n=41, 16.4%) and dermatologic effects (n=27, 10.8%). The rate of discontinuation of treatment for patients aged ≥65years was significantly higher than for patients aged <65years, for both men (P<0.0001) and women (P=0.0121). Moreover, the frequency of discontinuation due to neurovegetative symptoms, depression-related syndrome, and hematologic effects for men aged ≥65years was significantly higher than for those aged <65years (P=0.0001, P=0.0016, and P=0.0170, respectively), but not for women. Conclusion: Premature discontinuation due to the adverse effects of PEG-IFN α-2b and RBV treatment by patients with chronic HCV infection is mainly due to neuropsychiatric symptoms and is more common for older than for younger patients.

Original languageEnglish
Pages (from-to)1233-1240
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume27
Issue number7
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Ribavirin
Chronic Hepatitis C
Virus Diseases
Hepacivirus
Interferons
Liver Diseases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection : Results from Kyushu University Liver Disease Study. / Ogawa, Eiichi; Furusyo, Norihiro; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, Hideyuki; Tanabe, Yuichi; Satoh, Takeaki; Maruyama, Toshihiro; Nakamuta, Makoto; Kotoh, Kazuhiro; Azuma, Koichi; Dohmen, Kazufumi; Shimoda, Shinji; Hayashi, Jun.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 27, No. 7, 01.01.2012, p. 1233-1240.

Research output: Contribution to journalArticle

Ogawa, Eiichi ; Furusyo, Norihiro ; Kajiwara, Eiji ; Takahashi, Kazuhiro ; Nomura, Hideyuki ; Tanabe, Yuichi ; Satoh, Takeaki ; Maruyama, Toshihiro ; Nakamuta, Makoto ; Kotoh, Kazuhiro ; Azuma, Koichi ; Dohmen, Kazufumi ; Shimoda, Shinji ; Hayashi, Jun. / Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection : Results from Kyushu University Liver Disease Study. In: Journal of Gastroenterology and Hepatology (Australia). 2012 ; Vol. 27, No. 7. pp. 1233-1240.
@article{59239cedab774b8aa98f5d17f1a35b08,
title = "Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study",
abstract = "Background and Aims: Pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) treatment of chronic hepatitis C virus (HCV) infection is associated with a substantially elevated risk of discontinuation. The aim of this study is to evaluate the reason for premature discontinuation during PEG-IFN α-2b and RBV treatment due to adverse effects in patients with chronic HCV infection. Methods: A total of 2871 Japanese patients who had chronic HCV infection treated with PEG-IFN α-2b and RBV were screened. We prospectively investigated the reasons for premature discontinuation of treatment classified by sex and age, and analyzed the timing of discontinuation. Results: Of the 2871 patients, 250 (8.7{\%}) discontinued treatment because of adverse effects. The main reasons for premature discontinuation were neurovegetative symptoms (n=77, 30.8{\%}), depression-related syndrome (n=46, 18.4{\%}), hematologic effects (n=41, 16.4{\%}) and dermatologic effects (n=27, 10.8{\%}). The rate of discontinuation of treatment for patients aged ≥65years was significantly higher than for patients aged <65years, for both men (P<0.0001) and women (P=0.0121). Moreover, the frequency of discontinuation due to neurovegetative symptoms, depression-related syndrome, and hematologic effects for men aged ≥65years was significantly higher than for those aged <65years (P=0.0001, P=0.0016, and P=0.0170, respectively), but not for women. Conclusion: Premature discontinuation due to the adverse effects of PEG-IFN α-2b and RBV treatment by patients with chronic HCV infection is mainly due to neuropsychiatric symptoms and is more common for older than for younger patients.",
author = "Eiichi Ogawa and Norihiro Furusyo and Eiji Kajiwara and Kazuhiro Takahashi and Hideyuki Nomura and Yuichi Tanabe and Takeaki Satoh and Toshihiro Maruyama and Makoto Nakamuta and Kazuhiro Kotoh and Koichi Azuma and Kazufumi Dohmen and Shinji Shimoda and Jun Hayashi",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2011.06965.x",
language = "English",
volume = "27",
pages = "1233--1240",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection

T2 - Results from Kyushu University Liver Disease Study

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Kajiwara, Eiji

AU - Takahashi, Kazuhiro

AU - Nomura, Hideyuki

AU - Tanabe, Yuichi

AU - Satoh, Takeaki

AU - Maruyama, Toshihiro

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Azuma, Koichi

AU - Dohmen, Kazufumi

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background and Aims: Pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) treatment of chronic hepatitis C virus (HCV) infection is associated with a substantially elevated risk of discontinuation. The aim of this study is to evaluate the reason for premature discontinuation during PEG-IFN α-2b and RBV treatment due to adverse effects in patients with chronic HCV infection. Methods: A total of 2871 Japanese patients who had chronic HCV infection treated with PEG-IFN α-2b and RBV were screened. We prospectively investigated the reasons for premature discontinuation of treatment classified by sex and age, and analyzed the timing of discontinuation. Results: Of the 2871 patients, 250 (8.7%) discontinued treatment because of adverse effects. The main reasons for premature discontinuation were neurovegetative symptoms (n=77, 30.8%), depression-related syndrome (n=46, 18.4%), hematologic effects (n=41, 16.4%) and dermatologic effects (n=27, 10.8%). The rate of discontinuation of treatment for patients aged ≥65years was significantly higher than for patients aged <65years, for both men (P<0.0001) and women (P=0.0121). Moreover, the frequency of discontinuation due to neurovegetative symptoms, depression-related syndrome, and hematologic effects for men aged ≥65years was significantly higher than for those aged <65years (P=0.0001, P=0.0016, and P=0.0170, respectively), but not for women. Conclusion: Premature discontinuation due to the adverse effects of PEG-IFN α-2b and RBV treatment by patients with chronic HCV infection is mainly due to neuropsychiatric symptoms and is more common for older than for younger patients.

AB - Background and Aims: Pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) treatment of chronic hepatitis C virus (HCV) infection is associated with a substantially elevated risk of discontinuation. The aim of this study is to evaluate the reason for premature discontinuation during PEG-IFN α-2b and RBV treatment due to adverse effects in patients with chronic HCV infection. Methods: A total of 2871 Japanese patients who had chronic HCV infection treated with PEG-IFN α-2b and RBV were screened. We prospectively investigated the reasons for premature discontinuation of treatment classified by sex and age, and analyzed the timing of discontinuation. Results: Of the 2871 patients, 250 (8.7%) discontinued treatment because of adverse effects. The main reasons for premature discontinuation were neurovegetative symptoms (n=77, 30.8%), depression-related syndrome (n=46, 18.4%), hematologic effects (n=41, 16.4%) and dermatologic effects (n=27, 10.8%). The rate of discontinuation of treatment for patients aged ≥65years was significantly higher than for patients aged <65years, for both men (P<0.0001) and women (P=0.0121). Moreover, the frequency of discontinuation due to neurovegetative symptoms, depression-related syndrome, and hematologic effects for men aged ≥65years was significantly higher than for those aged <65years (P=0.0001, P=0.0016, and P=0.0170, respectively), but not for women. Conclusion: Premature discontinuation due to the adverse effects of PEG-IFN α-2b and RBV treatment by patients with chronic HCV infection is mainly due to neuropsychiatric symptoms and is more common for older than for younger patients.

UR - http://www.scopus.com/inward/record.url?scp=84862654183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862654183&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2011.06965.x

DO - 10.1111/j.1440-1746.2011.06965.x

M3 - Article

C2 - 22098185

AN - SCOPUS:84862654183

VL - 27

SP - 1233

EP - 1240

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 7

ER -